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Conventional and electronic (e-) cigarettes deliver nicotine to the bloodstream, resulting in 
significant production of its primary metabolite – cotinine.1,2 Nicotine is known to affect the 
cardiovascular system through sympathetic nervous system activation. This increases 
myocardial contractility, heart rate, blood pressure and coronary vasoconstriction.3,4 Clinical 
studies into nicotine primarily focus on nicotine replacement therapy (NRT) use, which 
typically produces nicotine concentrations half those of smoking, vaping or using smokeless 
tobacco. Whilst reviews have not found an association between NRT use and cardiovascular 
morbidity,5,6 studies into smokeless tobacco use have found associations with fatal coronary 
artery disease;7 with mortality rates halving in individuals who quit product use after a 
myocardial infarction.8 It is not possible however to determine whether this mortality is 
attributable to nicotine. 
Other constituents of conventional and electronic cigarettes have raised more concern. 
Cigarettes produce carbon monoxide (CO) which contributes to carboxyhaemoglobin 
formation, increasing blood viscosity and contributing to thrombogenesis. Both products 
deliver fine (PM2.5) and ultra-fine (PM0.1) particulate matter.
9,10 These may trigger 
pathophysiological processes including vascular inflammation and platelet activation,11–15 
with chronic exposure constituting a cardiovascular risk factor.16 Thermal degradation of e-
cigarette solvent carriers glycerol and propylene glycol can also produce carbonyls, such as 
formaldehyde, acetaldehyde, and acrolein,13,17  that may cause pathophysiological changes 
once broken down into reactive oxidant species,18–21 potentially contributing to 
cardiomyopathy.22 E-cigarettes liquids have also been manufactured with numerous 
flavourings, such as cinnamaldehyde, which may have cardiotoxic effects.23 Heavy metals 
such as cadmium and lead have been detected in certain e-cigarette aerosols,24 which have 
been associated with hypertension25 and coronary artery disease respectively.26 It is worth 
noting however that mere detection of toxicants in aerosols does not mean they will reach 
the bloodstream in toxic quantities. 
Middlekauff recently developed a model illustrating four mechanisms by which e-cigarettes 
may increase the risk of cardiovascular disease: (i) Sympathetic nerve activation; (ii) 
oxidative stress; (iii) Endothelial dysfunction and (iv) platelet activation. These mechanisms 
may induce arrhythmias, atherosclerosis and acute ischaemia. Whilst investigation of these 
long-term sequelae is problematic due to the inchoate nature of e-cigarettes, their inducing 
mechanisms can be investigated through various biomarkers including (i) haemodynamic 
changes; (ii) oxidant and antioxidant levels; (iii) measures of arterial stiffness and (iv) platelet 















This study systematically reviews the evidence of physiological and pathophysiological 
cardiovascular effects after direct exposure to electronic cigarettes and discusses the 
implications for cardiovascular disease.  
Methods 
Four researchers conducted the review applying Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines.28 
Search strategy 
A literature search was conducted on 17 July 2017 and updated on 12 th June 2019 using 
Ovid MEDLINE and Embase databases from 1996 to 11 June 2019. The following search 
terms were utilised: ‘e-cig*’ or ‘electronic cig*’ or ‘e-liquid’ or ‘e-juice’ or ‘electronic nicotine 
delivery system’ or ‘vape’ combined with ‘cardi*’ or ‘myocardi*’ or ‘coronary’ or ‘heart’ or 
‘vascular’ or ‘endotheli*’. Reference lists of included articles and pertinent policy papers were 
examined for additional citations and a secondary literature search was conducted through 
Web of Science. 
Inclusion, exclusion and study eligibility criteria 
Experimental studies pertaining to (human) in vitro, animal, or human cardiovascular effects 
of e-cigarette use were included. Full details are presented in Appendix 1. Studies had to 
report quantifiable biomarkers of cardiovascular effects or cardiovascular pathology. Non-
experimental studies were excluded but are summarised in web appendix 2. Human studies: 
Eligibility criteria: adults with or without cardiovascular disease, independent of smoking 
status and age.  
Data extraction and synthesis 
Extraction tables collated data on study, participant, and intervention characteristics together 
with study results. Despite the publication of a recent meta-analysis of haemodynamic 
outcomes from e-cigarette use,29 we decided to synthesised extracted data narratively due 
to concerns about study heterogeneity. We organised our findings based on a conceptual 
model of potential pathways that draws on previous papers, including that developed by 
Middlekauff (Figure 1). 27 
Conflict of interest in studies 
To assess any influence of conflict of interest (COI), influence not generally captured by 
traditional quality assessment tools, on appraisal of e-cigarettes one reviewer extracted 
outcome data and conclusions verbatim from included papers and another blindly judged 
whether results and/or conclusions were supportive of e-cigarette use. COI status was 















presentations by the individuals involved) that authors or studies received funding or other 
assistance from tobacco and/or e-cigarettes manufacturers. Chi-squared with two-tailed 
Fisher’s Exact Test assessed significance of relationships between COI status against 
potentially harmful cardiovascular outcomes and conclusions supportive of e-cigarette use. 
Quality assessment 
Quality of studies was assessed using Cochrane Risk of Bias (RoB) tools.30 RoB status was 
then assessed against outcome data and conclusions using Chi-squared tests, with 
significance measured using two-tailed Fisher’s Exact Test because of the small numbers of 
studies. Study heterogeneity precluded assessing publication bias by means of a funnel plot. 
RoB was also compared in studies that we did or did not identify as having potential conflict 
of interest (appendix 6). 
Results 
Study selection 
The electronic search identified 766 records with an additional 10 from reference lists 
(Figure 2). After removal of duplicates, 563 records were screened for inclusion by title and 
abstract, leaving 82 full-text articles to be assessed for eligibility, when 44 articles were 
excluded due to: inappropriate study designs (non-experimental or lacking 
control/comparators) (n=10), no relevant outcome measures (n=1), inappropriate study 
population (n=4) or had no full-text articles associated with their abstracts (n=29) (web 
appendix 2). 37 articles were included in the review. 
Study characteristics 
This review included randomised controlled-trials (n=8)31–38; randomised crossover studies 
(n=10)39–48; non-randomised controlled trials (n=13)49–61 and non-randomised crossover 
studies (n=7)62–68. These articles studied human subjects (n=24)32,33,35,37,39–48,56,57,61–68, animal 
subjects (n=6)36,38,51,53,58,60 and a range of human cardiovascular cells types and platelets 
(n=8)31,34,49,50,52,54,55,59. The total duration of exposure of cells to e-cigarette aerosol extract 
(eCAE) in in vitro studies ranged from 4 hours to 72 hours (table 1, appendix 3). Sample size 
in human studies ranged from 10 to 408 participants, with attrition ranging from 0% to 39%. 
In human cross-over studies the washout period ranged from 1 hour to 4 weeks (table 2). 
Participant characteristics 
Only 11% of human studies investigated solely non-smoking populations.35,41,42,61 45.8% of 
human studies included subjects without prior use of e-cigarettes and understanding of 
vaping topography (n=11),33,35,40–42,61,63,65–68 whilst a further 33.3% of studies did not state 















chemically verified baseline smoking abstinence (n=11).37,39,66,40,43,45,47,48,63–65. Mean age of 
human subjects, who were healthy volunteers, ranged from 22.9 to 46.6 years old.  
Intervention characteristics 
Interventions in in vitro studies are summarised in Table 3 and in human and animal studies 
in Table 4. The brand and generation of e-cigarettes reported varied widely – if reported at 
all. Only three studies reported utilising newer generation devices.36,43,45 Only 44.7% of 
studies reported any electrical characteristics of devices (n=17), with voltage varying from 
3.0 to 5.0 volts and resistance varying from 0.4 to 2.4 ohms. Few studies included 
independent chemical analyses of e-liquids (n=6)33,40,45,50,56,67 and only Schweitzer et al. 
tested resultant vapour constituents for presence of newly formed oxidation products.50 Only 
one in vitro study measured e-cigarette heating coil temperature55 whilst only two considered 
high coil temperatures (table 3).54,55 Reported nicotine concentration in eCAE solution varied 
from 0 to 36mg/mL with only 37.5% of human and animal studies estimating nicotine 
delivery, through plasma nicotine and/or urinary cotinine concentrations 
(n=9).36,39,42,45,47,60,63,65,66 Notably, both Eissenberg et al. and Vansickel et al. reported no 
statistically significant increase in blood nicotine concentration after e-cigarette use, with 
participants being under-exposed.63,65  
Only 50% of human studies chemically verified abstinence (n=12), 33,35,65,66,37,39,40,43,45,47,48,64. 
Most studies did not report frequency of abstinence testing, with Farsalinos et al. (2016) 
having periods up to 24 weeks without assessing abstinence.37 There was significant inter-
study variation in inhalation regime. Some studies controlled for duration and intensity of  
‘vaping’ whilst others allowed ad libitum use. Notably, Pywell et al. utilised a vaping protocol 
based on smoking protocols used in the literature but abandoned it because of nausea.68 
Only Chaumont et al. assessed subjects’ tolerance to vaping prior to investigation.45 
Study results: in vitro studies 
These are summarised in Table 5.  
Oxidative stress 
Three studies found statistically significant increases in reactive oxygen species (ROS) 
associated with endothelial injury.49,52,55 Teasdale et al. did not however find significant 
upregulation in expression of genes involved in the oxidative stress pathway.54 
Endothelial cellular function 
Four studies reported statistically significant reductions in endothelial cell viability when 
exposed to certain eCAE,49,52,55,59 whilst Lee et al. identified significant impairment in 















compared to non-smokers.52 Lee et al. also identified increased endothelial cell tube 
formation, reflective of increased angiogenesis.69 Other cardiotoxic effects identified included 
DNA damage,49 cell morphological changes55 and reduced cell metabolic activity.31 These 
changes may constitute a mechanism for endothelial dysfunction in vivo, however caution 
should be taken when extrapolating from in vitro findings.  
 
Statistically significant reductions in endothelial cell density31 and proliferation55 (recognised 
indicators of endothelial injury and dysfunction) were detected in eCAE exposures in one 
study each. Lee et al. found significant inhibition of endothelial cell migration,52 whilst Taylor 
et al. found no significant inhibition after eCAE exposure. This inhibition has been associated 
with impaired vascular repair after endothelial dysfunction induced by smoking.59 
Schweitzer et al. identified increased endothelial cell barrier disruption50 after eCAE 
exposure. In vascular pathologies, endothelial barrier disruption is caused by pro-
inflammatory stimuli destabilising endothelial intracellular junctions. The resultant barrier 
disruption permits migration of immune cells into the arterial intima – inducing vascular 
inflammation.70  
Endothelial-complement interactions 
Barber et al. investigated the effect of eCAE on deposition of complement factors on 
endothelial cell surfaces, endothelial expression of gC1qR and cC1qR and endothelial 
complement inhibitors. All eCAE exposures were associated with statistically significant 
increases in C1q and C4d complement deposition and expression of gC1qR and cC1qR 
cellular proteins, with some extracts causing statistically significant complement inhibitor 
expression.31 Interestingly, endothelial C1q deposition did not increase when cells were 
exposed to smoke extract from conventional cigarettes. In Vivo, these endothelial-
complement interactions have been associated with increased endothelial dysfunction - 
contributing to atherosclerosis.71,72 
Platelet function 
Hom et al. reported significant increases in platelet aggregation, adhesion, activation and 
complement deposition after exposure to eCAE.34 These changes have been invoked as a 
mechanism for increased risk of thrombosis after cigarette smoking.73 
Study results: animal studies 
















Lee et al. reported statistically significant increases in two mutagens (O6-
methyldeoxyguanosines and γ-hydroxy-1,N2-propano-deoxyguanosine) in cardiac tissue of 
mice exposed to eCAE.38 Espinoza-Derout et al. identified cardiomyocyte mitochondrial 
nuclear damage and cytoplasmic abnormalities; as well as intramyocardial lipid 
accumulation and reduced expression of a cardioprotective gene after exposure to eCAE.53 
Olfert et al. reported statistically significant increases in left ventricular mass of mice after 
chronic exposure to e-cigarette vapour but not those exposed to cigarette smoke.36 
Espinoza-Derout et al. however observed no significant change.53 Olfert et al. observed no 
significant decreases in fractional shortening and ejection fraction in mice exposed to e-
cigarette vapour,36 whilst Espinoza-Derout et al. observed both of these findings.53 Shi et al. 
found no significant effects of vaping on cardiac contractility, fibrosis or geometric 
properties.51  
Vascular function 
Kaisar et al. reported significant increases in three markers of vascular inflammation 
(PECAM-1, VCAM-1, ICAM-1) after e-cigarette vapour inhalation.58 Espinoza-Derout et al.  
identified increased expression of inflammatory and apoptotic genes53 associated with 
atherosclerotic lesion formation74 and ROS-induced heart failure.75 Olfert et al. reported 
significant increases in pulse wave velocity (a measure of arterial stiffness associated with 
endothelial dysfunction76) in mice after long-term e-cigarette vapour inhalation. Furthermore, 
vapour inhalation led to an increased aortic vasoconstrictive response to (the 
vasoconstrictor) phenylephrine and a reduced aortic vasodilatory response to (the 
vasodilator) methacholine compared to mice exposed to filtered air as a control. These 
vascular dysfunctions may also be associated with increased risk of hypertension.77 No 
significant difference in aortic vasodilation was identified however in response to (the 
vasodilator) nitroprusside between mice exposed to e-cigarette vapour and filtered air. Urine 
cotinine (a nicotine biomarker) level in mice exposed to e-cigarette vapour was 
approximately half that of those exposed to cigarette smoke, yet vascular damage was 
similar, suggesting a role for mechanisms other than those involving nicotine.36 Shi et al, 
identified a significant increase in angiogenesis, which could ultimately contribute to 
atherogenesis.51 Most notably, Espinoza-Derout et al. identified statistically significant 
















Platelet function and haemostasis 
Qasim et al. reported statistically significant increases in platelet aggregation, alpha particle 
secretion, dense particle secretion, platelet-integrin activation and platelet resistance to 
inhibition by prostacyclin but not platelet count following eCAE exposure. They also 
identified significant decreases in bleeding time (indicative of increased haemostasis) and 
occlusion time (indicative of increased thrombogenesis),60 whilst Kaisar et al. reported 
statistically significant decreases in circulating thrombomodulin in mice - a molecule 
protective against thrombosis.58  
Study results: human studies 
Sympathetic nerve activation  
18 studies measured heart rate as a biomarker of high sympathetic nerve activation – a 
state associated with increased cardiovascular risk.78 Most studies reported increases 
(n=14),35,39,41–46,48,56,57,64,65,67 and some decreases (n=2)33,37 after e-cigarette use. Seven of 
these studies reported statistically insignificant changes,32,37,41,44,63–65 and one reported 
clinically insignificant changes.32  
17 studies investigated resting blood pressure as a proxy for sympathetic nerve activation. 
These found both increases (n=10)35,39,42,43,45–47,56,57,64 and decreases (n=4)33,37,41,67 in systolic 
pressure and increases (n=9)35,39,41–43,45,47,56,57 and decreases (n=3)33,37,64 in diastolic 
pressure, with differing degrees of significance. Fogt et al. assessed the effect of electronic 
cigarette use on exercising peripheral blood pressure, identifying significant increases in 
systolic pressure compared to nicotine-free e-cigarettes.41 Pywell et al. investigated the 
microcirculation of the hand following e-cigarette use, identifying statistically significant 
decreases in both superficial and deep flow, potentially associated with worse microvascular 
surgical outcomes.68  
Assessments of acute changes in heart rate and blood pressure have limited prognostic 
value. Therefore, Moheimani et al. investigated measures of abnormal heart rate variability 
(HRV), (a better proxy for cardiac sympathetic nerve activity), associated with increased 
cardiovascular mortality in individuals with known and unknown cardiovascular morbidity.79–
81 They identified a statistically significant decrease in cardiac vagal tone and an increase in 
sympathetic tone after e-cigarette use,42 whilst Sumartiningsih et al. identified significant 
increases in exercising HRV after vaping compared to the control group.46 Finally, Farsalinos 
et al. identified no significant effect of vaping on myocardial function after very brief 
















Oxidative stress is an important mechanism in the development of atherosclerosis from 
cigarette smoking.82 Two studies found significant increases in two ROS (sNOx2-dp and iso-
PGF2a) and a significant decreases in vitamin E levels and nitrogen oxide bioavailability, 
which are protective against ROS.47,62 Biondi-Zoccai et al. also identified significant 
increases in the ROS hydrogen peroxide (H2O2) and significant decreases in HBA% 
(protective H2O2 breakdown activity).
47 Ikonomidis et al. found significant oxidative stress 
after e-cigarette use, as measured by malondialdehyde (MDA);44 however Moheimani et al. 
did not find any significant acute effect of e-cigarette use on oxidative stress burden, as 
measured by paraoxonase-1 (PON-1) activity.42 Chaumont et al. identified significant 
increases in plasma concentrations of myeloperoxidase, an enzyme involved in oxidative 
stress pathways,45 which has been associated with increased cardiovascular risk.83 
However, no significant increases were identified in the oxidative stress-associated protein-
bound 3-chlorotyrosine or homocitrulline.45 Two studies found significant increases in 
circulating CD40L after e-cigarette use, which leads to endothelial cell activation and the 
production of ROS.47,66 Finally, Chatterjee et al. found significant increases in ROS 
generation and C-reactive protein (a biomarker of inflammatory processes including 
atherothrombosis)84, as well as significant decreases in (protective) NO metabolites after 
vaping.61 
Endothelial function 
Endothelial dysfunction is prognostic of atherosclerosis.85 Studies reported various 
measures of arterial stiffness, indicative of endothelial dysfunction. Carnevale et al. 
measured arterial flow-mediated dilatation (FMD) finding significant impairment.62 However, 
Szołtysek-Bołdys et al. reported insignificant changes in arterial stiffness index (SI) and 
reflection index (RI) after e-cigarette use.64 Four studies identified significant increases in 
augmentation index normalised to a heart rate of 75 beats per minute (AIx75),43–45,48 whilst 
five studies reported significant increases in pulse wave velocity (PWV) after e-cigarette 
use.43–45,48,57 
Kerr et al. found an increase in reactive hyperaemia index,67 an indicator of endothelial 
dysfunction,86 whilst Antoniewicz et al. found significant increases in circulating reparative 
endothelial progenitor cells (EPCs) - suggesting vascular injury from vaping.40 Chatterjee et 
al. found significant increases in soluble and endothelial ICAM-1 (an adhesion molecule 
involved in endothelial activation and dysfunction),61 however Kerr et al. did not.67 Finally, 
Chaumont et al. identified significantly reduced vasodilatory responses to the endothelial-















the endothelial-independent vasodilator sodium nitroprusside after vaping, suggestive of 
endothelial dysfunction.45 
Platelet activation 
Smoking can induce pathophysiological platelet activation, resulting in thrombosis and in 
turn ischaemia and potentially infarction.82 Kerr et al. found significant increases in platelet 
microparticle secretion,67 whilst Nocella et al. found significant increases in platelet 
aggregation after e-cigarette use.66 Two studies found significant increases in soluble 
Platelet (P-) selectin 47,66 whilst Kerr et al. found a significant decrease in P-selectin.67 
Summary of findings and proposed mechanisms 
Based on the findings we propose mechanisms of the complex effects of e-cigarettes on the 
heart (table 7). 
 
Conflicts of interest in studies 
21.1% of studies included in this review were deemed to have a potential COI 
(n=8)32,33,37,39,49,56,59,64 utilising funding, materials and/or researchers supplied by tobacco or 
e-cigarette manufacturers (web appendix 4).  
74.3% of all studies found a potentially harmful cardiovascular effect (n=29). Only two of the 
eight papers (25%) deemed to have a potential COI reported a potentially harmful 
cardiovascular effect.54,58 In contrast, 27 of the 30 (90%) without apparent COI reported such 
an effect. The difference was significant (Fisher’s Exact Test, P=0.0007). Notably, two of the 
three studies without a COI that did not identify a cardiovascular effect appeared to have 
ineffective nicotine delivery to the bloodstream.63,65 
Seven of the eight studies with a potential COI had conclusions that were supportive of 
electronic cigarette use32,33,37,39,49,56,59 in addition to one study with no apparent COI.54 24 of 
the 29 studies without a COI had conclusions that were unsupportive of e-cigarette use. This 
difference was highly significant (Fisher’s Exact Test, p<0.0001). Notably, six studies had 
conclusions that were neutral,41,46,51,64,65,68 of which one had a COI.64 
Quality assessment 
Details of the quality assessment undertaken are described in web appendix 5. 34.2% of 
included studies were deemed to have a moderate-high risk of bias (n=13). 11 of these are 
opinions on e-cigarettes, with 6 (54.5%) having conclusions that were supportive of e-
cigarette use (appendix 6).   
Discussion  















38 experimental studies were identified. 90% of studies deemed to be without COI found 
potentially harmful effects on the cardiovascular system. Only two of eight studies deemed 
to have a potential COI reported a potentially harmful cardiovascular effect, whilst six of 11 
studies with moderate-high risk of bias had conclusions that were supportive of e-cigarette 
use.  
Human studies largely showed increases in heart rate and blood pressure as well as 
abnormalities in heart-rate variability, suggestive of sympathetic nerve activation. Both in 
vitro and in vivo studies showed an increase in reactive oxygen species production and a 
reduction in anti-oxidants after e-cigarette exposure, constituting an atherosclerotic risk. This 
was evidenced in one murine studying which found significantly greater atherosclerotic 
plaque development in mice exposed to e-cigarette vapour. In vitro studies identified 
disordered endothelial cellular structure, function and interactions; murine studies identified 
vascular inflammatory markers and angiogenesis, whilst human studies identified increased 
arterial stiffness - all suggestive of endothelial dysfunction. Platelet haemostatic processes 
were reported across murine, human in vitro and human in vivo studies, suggestive of an 
increased thrombotic risk.  
Notably, vaping but not smoking increased endothelial (c)1q deposition, reactive hyperaemia 
and murine left ventricular mass. These changes may be suggestive of endothelial 
dysfunction and cardiac remodelling. 
Consistency of findings with previous reviews 
Benowitz undertook two literature reviews of the cardiovascular effects of nicotine3 and e-
cigarettes88 respectively but neither were conducted systematically nor limited to 
experimental studies. They noted the pharmacological plausibility of adverse cardiovascular 
outcomes of nicotine (and other vaporised e-cigarette compounds), particularly in those with 
primary cardiovascular disease.  
Qasim et al. also reviewed this literature but did not use a systematic methodology or restrict 
studies to experimental designs. It focused on hypothetical effects of individual constituents, 
identifying carbonyls and their breakdown products as potential sources of oxidative stress 
and arguing that fine particulate matter in e-cigarette vapour could increase intracellular 
calcium in addition to affecting the autonomic nervous system and modifying heart rate 
variability, collectively contributing to arrhythmias.89  
Two further reviews were published while this one was under review. One is a narrative 
review which addresses a series of practical questions.90 The other conducted meta-
analyses of the associations between e-cigarette use and haemodynamic effects, identifying 















pressure.29 No previous review focused on the cardiovascular system examined potential 
conflicts of interest.  
Limitations of the primary literature 
Overall, there were many methodological weaknesses in the studies included. Their utility 
was further compromised by the number of papers with potential COI. A comprehensive 
exploration of limitations is in appendix 7 but some of the most important are as follows. 
First, there is a huge product variation. Liquids tested represent only a very small proportion 
of the seemingly innumerable variants available on the market. Second, most studies utilised 
conventional cigarettes, one of the most harmful legal products, as a study comparator. This 
may have resulted in the neglect of other potential harms, not associated with cigarette 
smoking, such as those arising from the aerosol (solvent carriers and flavours) or the 
solvent. Few investigated nicotine-free e-cigarettes. Third, some in vitro studies exposed 
cells to extracts with nicotine concentrations which might be greater than those delivered to 
the bloodstream from vaping. Fourth, many human experimental studies had small sample 
sizes and lacked blinding or randomisation, whilst certain cross-over studies utilised short 
washout periods. There are distinct differences in electronic and conventional cigarette 
topography, with e-cigarettes requiring longer puff length and vaping duration to attain 
comparable nicotine levels. As participants in experiments often were e-cigarette-naïve 
smokers, this implied a risk of under-exposure. Some exposures were extremely small, with 
two exposing subjects to only 9 puffs. Variations in device voltage, vaporizers, e-liquid levels 
and pH may also influence nicotine, and other compound, delivery. Failure to assess plasma 
nicotine made it difficult to ascertain whether there was enough time after vaping to reach 
peak delivery, or whether it was too long and effects were waning. Fifth, few studies 
assessed abstinence but those that did found some subjects self-reporting as abstinent were 
current smokers. Sixth, heating coil pre-activation time, puff length, inter-puff intervals and 
total fluid consumption varied between intervention and comparator groups within studies, 
and between intervention groups across studies. Most human studies exposed participants 
to vaping for only a few minutes.  
Limitations of this review 
Appropriateness of search strategy 
Non-experimental studies were excluded on methodological grounds but most also point to 
potentially harmful cardiovascular effects, with three cross-sectional studies associating daily 
e-cigarette use (adjusted for conventional cigarette use) with increased risk of myocardial 
infarction.91–93  Longitudinal studies will be essential to elicit the long-term effects of vaping 
but the cohort studies we identified were small, with important methodological limitations. 















control/comparator groups or cross-over methodologies.94–96 Numerous conference 
abstracts lacked matching full-text papers.   
Limited range of outcome measures 
Cardiovascular disease results from many complex processes acting on different metabolic 
pathways and physiological mechanisms. Three metabolic studies in animals did not meet 
inclusion criteria but may have long-term cardiovascular implications, reporting significant 
increases in circulating cholesterol and triglycerides97 and hyperglycaemia98, following 
exposure to e-cigarette vapour while one study found that nicotine impaired transfer of 
glucose across the blood brain barrier in ischaemic conditions, with implications for recovery 
from ischaemic stroke.99  
Generalisability of findings 
Samples of aerosols tested may not be generalisable to other products. The short duration 
of most interventions also limits insights on long-term outcomes. Additionally, in vitro/animal 
studies may not be generalisable to human populations.  
The absence of never-smoking subjects in most studies prevents generalisation of findings 
to never-smokers using e-cigarettes. This is a significant limitation as adolescents represent 
a potential at-risk group, with proportionally the highest uptake of e-cigarettes,100 which in 
turn may be predictive of smoking initiation in young people.101–104 Interestingly, a recent 
post-hoc analysis by Carnevale et al. found that never-smokers had greater adverse 
oxidative and vascular reactions to vaping (comparable to those of smoking a cigarette) than 
experienced by smokers. Additionally, women taking the oral contraceptive (a common 
potential at-risk group that has not yet been considered) have significantly more 
unfavourable changes in vitamin E levels and fibromuscular dysplasia .105 
The prominence of 1st and 2nd generation e-cigarettes tested in these studies should be 
noted, as this is not reflective of current e-cigarette use - with many users owning 3rd and 4th 
generation devices. These have different nicotine delivery profiles and electrical 
characteristics, including controls over both wattage and voltage, which enables users to 
increase device power and consequently liquid consumption per puff,106 Studies have also 
shown higher voltage devices to produce more carbonyls.107 Notably, all three studies which 
reported to utilise newer generation devices identified potentially harmful cardiovascular 
outcomes.36,43,45 
Most of the primary literature compares cardiovascular consequences of electronic cigarette 
use with cigarettes or non-smoking. Whilst this makes it easier to elucidate the 
cardiovascular effects attributable to these devices, it is not generalisable to the vaping 















There may be few if any cardiovascular benefits for those who only reduce cigarette 
consumption,109 given the non-linear dose-response relationship between number of 
cigarettes smoked per day and cardiovascular disease.4,110 Exposure to even low levels of 
harmful constituents from e-cigarettes might have a pronounced effect on the cardiovascular 
system. A recent systematic review highlighted the potential for harmful health effects of 
passive exposure to electronic cigarette vapour.111 Finally, the studies included have mostly 
examined specific mechanisms whereas, in practice, what will matter is their combined 
effects: This will require long-term follow up studies. 
Conflict of interest 
We were only able to identify potential COI where it was reported, either in the papers 
included or others by the authors. However, there is growing evidence that conflicts can be 
concealed or nuanced, with a new area of scholarship emerging on this subject.112,113 The 
COIs identified in this paper were revealed by the authors themselves, as required by the 
journals. Whilst disclosing conflicts of interest is good practice, it does not negate the 
influence of said conflict, as even acknowledged financial support appears to influence 
outcomes.114,115 In the light of such findings, the British Medical Journal, American Thoracic 
Society, Tobacco Control and PLOS Medicine have already decided they will not publish 
tobacco industry–funded research.116 
Conclusion 
Primary studies suggest potentially harmful cardiovascular effects from electronic cigarettes, 
through inducing sympathetic nerve activation, oxidative stress, endothelial dysfunction and 
platelet activation. Notably, one murine study found e-cigarette aerosol accelerated 
atherosclerotic plaque formation.  It is concerning that COI status and median-high risk of 
bias were both significantly associated with the identification of no harmful cardiovascular 
effects. Further research is required to assess effects of electronic cigarettes in subjects with 
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study design; 
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Table 2 Characteristics of human (n=24) and animal experimental studies (n=6). 
Author & Year 
Conflict of 
interest 
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*subjects who underwent sham smoking not mentioned in methods – unclear if part of 40 original subjects or an 
additional 8 subjects. 
** Study design referred to enrolment of 6 regular e-cigarette smokers also but limited information is provided about 
these participants 
#Arterial stiffness measured by Stiffness Index (SI) and Reflection Index (RI). 
+ Serum NOX2-derived peptide, Serum nitric oxide and 8-Iso-Prostaglandin F2a, Serum Vitamin E, Flow Mediated 
Dilatation (FMD). 
^ Measured via PECAM-1, VCAM-1 and ICAM-1 markers. 
$ Subject attrition due to expected deaths associated with long-term murine studies. 
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* Research reference cigarette # confirmed by Nuclear Magnetic Resonance (NMR) and high-resolution mass spectroscopy + Platelets were exposed to nicotine 
















Table 4  Interventions in human (n = 24) and animal experimental studies (n=6) 
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Carnevale et al. 
(2016)62 
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D’Ruiz et al. 
(2017)33 
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Nocella et al. 
(2018)66 
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NS NS NS Not measured NS 
0 mg/mL 
3 mg/mL 
Not measured NS Not measured 
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Vlachopoulos 
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Derout et al. 
(2019)53 
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Kaisar et al. 
(2017)58 
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Lee et al. 
(2018)38 
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* Paper includes broken hyperlink to toxicological report # Measured every 2 weeks for 6 weeks, then after 12 weeks and finally after another 24 weeks        + Subject 
removal left to discretion of investigator. 























Table 5 Outcome results for in vitro studies (n = 8) 
Author 
(Year) 







Hom et al. 
(2016)34 
Platelet aggregation Increased P < 0.05 Increased P < 0.05 
Platelet adhesion Increased P < 0.05 Increased P < 0.05 
Platelet activation Increased P < 0.05 Increased P < 0.05 
Platelet c1q complement 
deposition 
Not increased P = NS - - 
Platelet c3b complement 
deposition 
Increased P < 0.05 - - 
Platelet c4d complement 
deposition 
Not increased P = NS - - 
Platelet c5b-9 
complement deposition 
Not increased P = NS - - 









P < 0.05 
Increased P = NS 
Endothelial gC1qR 
expression 
Increased P < 0.05 Increased P < 0.05 
Endothelial cC1qR 
expression 






P < 0.05 






P < 0.05 






P < 0.05 
Increased P = NS 
Anderson et 
al. (2016)49 
Cell viability Reduced P < 0.001 Reduced P <0.001 
Barber et al. 
(2016)31 
Cell viability Reduced 
(4/5) 
P < 0.05 
Reduced P = NS 







Reduced  P < 0.05 - - 
Reactive oxidative 
species (H2O2 levels) 
 
Increased P < 0.05 Increased P < 0.05 
Apoptosis  
(caspases 3/7 activity) 
Increased  p < 0.05 - - 
Endothelial function 
(tube formation) 
Increased P < 0.05 Increased P < 0.05 















and lipid uptake)  
Endothelial function (cell 
migration) 
Decreased p < 0.001 - - 
Cross-talk between 




Increased P < 0.05 - - 
Cross-talk between 




















of iPSC-ECs Affected  





et al. (2015)55 
Cell viability Reduced 
(5 / 11) 
P < 0.05 
Reduced P < 0.001 
Anderson et 
al. (2016)49 
DNA Damage Detected - Detected - 
Putzhammer 
et al. (2015)55 
Cell morphological 
alterations 
Detected - Detected - 
Barber et al. 
(2016)31 
Cell density Reduced P < 0.05 Reduced P < 0.05 
Putzhammer 
et al. (2015)55 
Cell proliferation Reduced 
(4 / 11) 
P < 0.001 
Reduced P < 0.001 
Taylor et al. 
(2017)59 
Cell migration Reduced P = NS Reduced P < 0.05 
Anderson et 
al. (2016)49 
Reactive oxygen species Increased P < 0.001 Increased P < 0.001 
Putzhammer 
et al. (2015)55 
Reactive oxygen species Increased 
(1 / 11) 
P < 0.001 
Increased P < 0.001 
Teasdale et al. 
(2016)54 
Upregulation of genetic 
markers of oxidative 
stress* 
No P = NS Yes P < 0.05 









Yes P < 0.0001 Yes P < 0.0001 
* (HMOX1, GCLM, OSGIN1, PAR4, CYP1A1, CYP1B1, IL8 and NTPX1) # Only for 5mM and 10mM not 2.5mM 

































Antoniewicz et al. 
(2019)48 
Heart rate Increased P = 0.001   - - 
No 
change 
Chaumont et al. 
(2018)45 
Heart rate Increased P < 0.0001 - - - 
Cooke et al. (2015)35 Heart rate Increased P ≤ 0.03 + - P = NS 
Decrea
sed 
Cravo et al. (2016)32 Heart rate 
No raw 
data 



























Farsalinos et al. 
(2014)56 










P = NS - - - 
Fogt et al. (2016)41 Heart rate Increased P=NS+ - - 
Increas
ed 
Franzen et al. 
(2018)43 







Ikonomidis et al. 
(2018)44 
Heart Rate Increased P = NS 
Increa
sed 
P = NS 
No 
change 






Moheimani et al. 
(2017)42 







Sumartiningsih et al. 
(2019)46 













P = NS - 
Vansickel et al. 
(2010)65 







Vlachopoulos et al. 
(2016)57 
Heart rate Increased 
(5-minute use) P 
= 0.57  
(30-minute use) 






Yan et al. (2014)39 Heart rate Increased 
(2/5)  


























P = 0.03+ 







P = 0.003+ 























Farsalinos et al. 
(2014)56 
Early diastolic 
peak velocity $ 







strain rate $ 







relaxation time – 
HR corrected $ 
Decrease
d 





















Increased P = NS 
Increa
sed 
P = NS 
No 
change 






P = NS 
Decre
ased 
P = NS 
No 
change 
Antoniewicz et al. 
(2019)48 
Systolic pressure Increased P = 0.227 - - 
Increas
ed 
Biondi-Zoccai et al. 
(2019)47 






Chaumont et al. 
(2018)45 
Systolic pressure Increased P < 0.0001 - - - 
Cooke et al. (2015)35 Systolic pressure Increased P ≥ 0.05 - - 
Decrea
sed 
Cravo et al. (2016)32 Systolic pressure 
No raw 
data 















Farsalinos et al. 
(2014)56 











P = 0.001 - - - 
Fogt et al. (2016)41 Systolic pressure 
Decrease
d 
P = 0.04+ - - 
Increas
ed 
Franzen et al. 
(2018)43 







Kerr et al. (2018)67 Systolic pressure 
Decrease
d 
P = NS 
Increa
sed 
P = NS - 
Moheimani et al. 
(2017)42 
Systolic pressure Increased P = NS - - 
Decrea
sed 
Sumartiningsih et al. 
(2019)46 






















al. (2014)64 sed 
Vlachopoulos et al. 
(2016)57 
Systolic pressure Increased 
(5-minute use) P 
< 0.05 (30-













Fogt et al. (2016)41 
Exercising systolic 
pressure 
Increased P=NS+ - - 
Increas
ed 




Increased P = NS 
Increa
sed 
P = NS 
Decrea
sed 
Antoniewicz et al. 
(2019)48 
Diastolic pressure Increased P = 0.062 - - 
Increas
ed 
Biondi-Zoccai et al. 
(2019)47 






Chaumont et al. 
(2018)45 
Diastolic pressure Increased P < 0.0001 - - - 
Cooke et al. (2015)35 Diastolic pressure Increased P = 0.001 - - 
Decrea
sed 
Cravo et al. (2016)32 Diastolic pressure 
No raw 
data 







D’Ruiz et al. (2017)33 Diastolic pressure 
Decrease
d 
 P < 0.0417 - - 
Decrea
sed 
Farsalinos et al. 
(2014)56 











P = 0.02  - - - 
Fogt et al. (2016)41 Diastolic pressure Increased P=0.04+ - - 
Increas
ed 
Franzen et al. 
(2018)43 







Kerr et al. (2018)67 Diastolic pressure 
No 
change 
P = NS 
Increa
sed 
P = NS - 
Moheimani et al. 
(2017)42 
Diastolic pressure Increased P = NS - - 
Decrea
sed 

















P = NS 
Increa
sed 
P = NS - 
Vlachopoulos et al. 
(2016)57 












Fogt et al. (2016)41 
Exercising 
diastolic pressure 
Increased P=0.02+ - - 
Increas
ed 
Pywell et al. (2018)68 
Superficial 
microcirculation 
of the hand 
Decrease
d 



















of the hand 
Decrease
d 
P < 0.05# - - 
Increas
ed 
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Augmentation 
Index 75 (Arterial 
Stiffness) 
Increased P = 0.013 - - - 
Antoniewicz et al. 
(2019)48 
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Index 75 (Arterial 
Stiffness) 
Increased P = 0.006 - - 
No 
change 
Franzen et al. 
(2018)43 
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Nocella et al. (2018)66 
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Increased P < 0.01+   
Increas
ed 
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P = NS+ - - - 
Platelet 
aggregation 
Increased Not stated+ - - - 
Platelet alpha 
particle secretion 
Increased P < 0.01+ - - - 
Platelet dense 
particle secretion 
Increased P < 0.01+ - - - 
Platelet integrin 
activation  





Increased P < 0.001+ - - - 


















P < 0.01 - - 
Uncha
nged 
Ejection fraction  
Decrease
d  














P = NS + - - - 














P = NS   
 
- - - 
Immuno-
fluorescent 
staining of CD31 
(heart tissue 
angiogenesis). 
Increased P = 0.01+ - - - 
Immuno-
fluorescent 
staining of CD34 
(heart tissue 
angiogenesis). 
































P = NSNS - - - 
# Significant for smokers but not for non-smokers     + Significance against control ^ Dual use   $ 
Myocardial function & Markers of vascular inflammation.  Grey highlight indicates animal study. ¶ 














Table 7. Summary of findings: the proposed complex pathogenic mechanisms of e-cigarettes’ effect on the heart 
 Proposed pathogenic mechanisms 
Angiogenesis Oxidative stress Endothelial dysfunction Sympathetic nerve 
system activation 
Platelet activation / 
anticoagulation inhibition 
Cardiac remodelling 
Biomarkers  ↑ CD31 
immunostaining
51 
 ↑ CD34 
immunostaining
51 











- Plasma myeloperoxidase45 
- Malondialdehyde53 
- ↑ Circulating CD40L 
(activates endothelial cells 
to release ROS)47 
- ↑ Serum C-Reactive 
Protein61 
 ↓ Antioxidant activity 
- Vitamin E levels47 
- NO bioavailability 
- Nitric Oxide62 metabolites61 
- HBA%47 
 ↑ Arterial stiffness 
- ↓ Flow-mediated 
dilatation47 
- ↑ Pulse-wave 
velocity48 
- ↑ Augmentation 
index x 7545 
 ↓ vasodilatory 
response to 
acetylcholine45 
 ↓ vasodilatory 
response to 
methacholine36 
 ↑ vasoconstrictive 
response to 
phenylephrine36 
 ↑ Endothelial 
progenitor cells40 
 ↑ Endothelial 
complement 
deposition31 
 ↑ Endothelial 
complement inhibitor 
expression31  
 Endothelial barrier 
disruption50 
 ↑ Reactive 
hyperaemia index67 







 ↑ Heart rate48 
 ↑  (Exercising)41 
systolic blood 
pressure47 
 ↑  (Exercising)41 
diastolic blood 
pressure47 
 Abnormal heart rate 
variability 











- Alpha particle 
secretion60 









- ↓ Bleeding time60 
- ↓ Occlusion time60 
 Altered cardiac structure: 
- ↑ Left ventricular mass36 
 Altered cardiac function: 
- ↓ Left Ventricular 
Ejection Fracture53 
- ↓ Left Ventricular 
Fractional Shortening53 
- ↓ Velocity of 
Circumferential Fibre 
Shortening53 


















 ↑ Endothelial cell: 
- Morphological 
alterations55 
- DNA damage49 
- Inhibition of 
migration52 
 ↓ Endothelial cell: 
- Proliferation55 
- Cell density31 





 Electronic cigarettes appear to be harmful to the cardiovascular system. 
 Numerous studies have substantial bias or a conflict of interest. 
 Studies with a conflict of interest appraise e-cigarettes more favourably. 
 Studies with substantial bias tend to appraise e-cigarettes favourably. 
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